Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis.

导出 OA

翻译打印收藏纠错

作者： Antonio,Lax ^[1] ; Fernando,Soler ^[1] ; Maria Josefa,Fernandez Del Palacio ^[2] ; Silvia,Pascual-Oliver ^[1] ; Miriam Ruiz,Ballester ^[1] ; Jose Javier,Fuster ^[3] ; Domingo,Pascual-Figal ^[3] ; Maria Del Carmen,Asensio-Lopez ^[4]

作者单位： Biomedical Research Institute Virgen de la Arrixaca (IMIB-Arrixaca), University of Murcia, 30120 Murcia, Spain. ^[1] Veterinary Hospital, University of Murcia 30100 Murcia, Spain. ^[2] Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain. ^[3] Cardiology Department, Hospital Virgen de la Arrixaca, IMIB-Arrixaca and University of Murcia, 30120 Murcia, Spain. ^[4] Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. ^[5]

关键词 MT: Oligonucleotides: Therapies and Applications YY1/HDAC4 axis anthracycline antimiRs treatment cardiotoxicity heart failure miR106b soluble ST2 isoform

DOI 10.1016/j.omtn.2023.04.031

PMID 37234747

发布时间 2023-05-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Molecular therapy. Nucleic acids

2023年32卷

704-720页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis.

Molecular therapy. Nucleic acids

相似文献

Molecular therapy. Nucleic acids

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis.

Molecular therapy. Nucleic acids

相似文献

Molecular therapy. Nucleic acids

相关期刊

检索历史清除